FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 64
Summary
- Conditions
- Gastric Cancer
- Advanced Solid Tumors
- Cervical Cancer
- Colorectal Cancer
- EGFR Positive Solid Tumor
- Head and Neck Cancer
- Small Cell Lung Cancer
- Urothelial Carcinoma
- Hepatocellular Carcinoma
- Squamous Cell Carcinoma
- HER2 Positive Breast Cancer
- Lymphoma
- NSCLC
- Melanoma
- Merkel Cell Carcinoma
- Pancreas Cancer
- Renal Cell Carcinoma
- Microsatellite Instability
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03841110
- Collaborators
- Not Provided
- Investigators
- Study Director: Jeff Chou, MD Fate Therapeutics
Get Well Soon